{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:44Z","timestamp":1792123664455,"version":"4.4.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec id=\"ab-eoi250050-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The current ocular Common Terminology Criteria for Adverse Events (CTCAE) mix eye signs with symptoms and lack standardized clinical photographs and experimental oncology drug dose modification recommendations. Robust reporting of ocular adverse events (AEs) is important to maintain patient safety and to guide the development of novel efficacious drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250050-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop improved ocular AE grading scales to reliably evaluate and grade ocular AEs in patients on experimental oncology drug therapy and to provide clear drug dose modification recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250050-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>A collaborative multicenter interspecialty working group consisting of oncologists and academic ophthalmologists from 11 academic centers in the US and ophthalmologists from the US Food and Drug Administration was assembled in February 2023 to form a consensus on new experimental oncology drug\u2013related ocular AE grading scales. The grading scales were released in June 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250050-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Expert consensus on novel experimental oncology drug\u2013related ocular AE grading scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250050-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six experimental oncology drug\u2013related ocular AE grading scales were developed with agreement from ophthalmologists and oncologists for use in antibody-drug conjugate clinical trials: visual acuity, eye symptoms, cornea, conjunctiva\/sclera, anterior chamber, and retina\/posterior segment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250050-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The new experimental oncology drug\u2013related ocular AE grading scales developed by the consensus panel were developed to be more concise, containing photographs where applicable, and to provide clear drug dose modification recommendations compared with the previous CTCAE. Use of these ocular AE grading scales may allow for more objective and consistent incidence measurements of ocular AEs throughout clinical trials and postmarketing, potentially facilitating safe testing of novel agents that may cause eye toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.3159","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:30:50Z","timestamp":1764865850000},"page":"62","source":"Crossref","is-referenced-by-count":9,"title":["Multicenter Interspecialty Consensus on Experimental Oncology Drug\u2013Related Ocular Adverse Event Reporting"],"prefix":"10.1001","volume":"144","author":[{"given":"Neel D.","family":"Pasricha","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco"},{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Texas Health Science Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim V.","family":"Farooq","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Lindgren","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerami D.","family":"Seitzman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco"},{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda F.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, San Francisco"},{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica G.","family":"Shantha","sequence":"additional","affiliation":[{"name":"Francis I. Proctor Foundation, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Skondra","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennie H.","family":"Jeng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston D.","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Casey Eye Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Colby","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, New York University Grossman School of Medicine, New York University Langone Health, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sobrin","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldev","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiley A.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, George Washington University, School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Division of Ophthalmology, Office of Specialty Medicine, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Silverstein","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Northwestern University Freiberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa C.","family":"Glencer","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Huppert","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jo","family":"Chien","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of California, San Francisco"},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"eoi250050r1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.leu.2401851","article-title":"Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.","volume":"14","author":"Naito","year":"2000","journal-title":"Leukemia"},{"issue":"1","key":"eoi250050r2","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape.","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"eoi250050r3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.","volume":"86","author":"Barker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"eoi250050r4","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1001\/jama.2011.1837","article-title":"Accelerating identification and regulatory approval of investigational cancer drugs.","volume":"306","author":"Esserman","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"eoi250050r5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study.","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"eoi250050r6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","article-title":"Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs).","volume":"12","author":"Lindgren","year":"2024","journal-title":"Curr Ophthalmol Rep"},{"key":"eoi250050r7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jtos.2023.08.009","article-title":"TFOS lifestyle report executive summary: a lifestyle epidemic\u2014ocular surface disease.","volume":"30","author":"Craig","year":"2023","journal-title":"Ocul Surf"},{"issue":"1","key":"eoi250050r9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00006416-198701000-00003","article-title":"QUEST: a process of pain assessment in children (continuing education credit).","volume":"6","author":"Baker","year":"1987","journal-title":"Orthop Nurs"},{"issue":"2","key":"eoi250050r10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/archopht.1985.01050020074024","article-title":"Effectiveness of a pinhole method for visual acuity screening.","volume":"103","author":"Loewenstein","year":"1985","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"eoi250050r11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archophthalmol.2011.248","article-title":"Understanding and reporting visual acuity measurements in publications of clinical research.","volume":"129","author":"Lopes","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"eoi250050r12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1475-1313.1999.00420.x-i1","article-title":"Validation of grading scales for contact lens complications.","volume":"21","author":"Efron","year":"2001","journal-title":"Ophthalmic Physiol Opt"},{"issue":"3","key":"eoi250050r13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. results of the First International Workshop.","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi250050r14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi250050r15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ajo.2009.11.019","article-title":"The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.","volume":"149","author":"Kempen","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"eoi250050r8","unstructured":"National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2842381\/jamaophthalmology_pasricha_2025_oi_250050_1767803522.36396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:01:06Z","timestamp":1768492866000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2842381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.3159","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}